bluebird bio (BLUE) is Fundamentally Overvalued - Cantor
Tweet Send to a Friend
Cantor Fitzgerald maintains Underweight on bluebird bio (NASDAQ: BLUE) price target of $122.00.Analyst Elemer Piros comments (emphasis StreetInsider) "At the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


